Wondering if Teleflex is a beaten down opportunity or a value trap at today’s price? Let us walk through what the numbers are really saying about the stock. After sliding 3.8% over the last week, ...

TFX's UroLift expansion and Barrigel traction support long-term growth, but high debt and FX headwinds keep the stock under pressure.

Teleflex (TFX) has quietly become a talking point after another choppy week for medtech names, with the stock drifting lower over the past week even as the past month’s performance turned positive.

The latest price target for Teleflex (NYSE:TFX) was reported by Truist Securities on May 5, 2025. The analyst firm set a price target for $137.00 expecting TFX to rise to within 12 months (a possible ...

The stock price of Teleflex (NYSE:TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a decline of 12% over the last month, while it was down ...

We believe F5 stock (NASDAQ: FFIV), an application security and cloud networking company, and Teleflex stock (NYSE: TFX), best known for its single-use medical products for common diagnostic and ...

Teleflex stock (NYSE: TFX), best known for its single-use medical devices for common diagnostic and therapeutic procedures, has seen a 31% fall this year, underperforming the broader S&P500 index, ...

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the surgical equipment & consumables - specialty industry, including Teleflex (NYSE:TFX) and its peers. The ...

Teleflex stock (NYSE: TFX), which provides instruments and consumables for laboratories, trades at $220 per share, 50% below the level seen in March 2021. TFX stock was trading at around $246 in early ...

Teleflex’s TFX broad Vascular Access portfolio is poised to continue to win shares through its category leadership in Central Venous Catheters (CVC), midlines and new launches. The company’s expansion ...